MapLight Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
MPLT$7.44+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(60,668) | $(22,340) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 162 | 166 |
| Stock-based compensation expense | 9,636 | 212 |
| Net amortization of premiums and accretion of discounts on investments | (814) | (257) |
| Non-cash lease expense | 229 | 212 |
| Loss on disposal of property and equipment | 4 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 2,475 | (193) |
| Accounts payable | (111) | (1,050) |
| Accrued expenses | (1,880) | (2,116) |
| Operating lease liabilities | (211) | (184) |
| Net cash used in operating activities | (51,178) | (25,550) |
| Cash flows from investing activities | ||
| Maturities and redemptions of investments | 67,031 | 37,500 |
| Purchases of property and equipment | (24) | — |
| Net cash provided by investing activities | 67,007 | 37,500 |
| Cash flows from financing activities | ||
| Payments of deferred offering costs | — | (52) |
| Proceeds from exercises of stock options and employee stock purchase plan issuances | 651 | 5 |
| Payment of employee tax obligations related to vesting of restricted stock units | (7,502) | — |
| Net cash used in financing activities | (6,851) | (47) |
| Increase in cash, cash equivalents, and restricted cash | 8,978 | 11,903 |
| Cash, cash equivalents and restricted cash at beginning of period | 46,936 | 38,460 |
| Cash, cash equivalents and restricted cash at end of period | $55,914 | $50,363 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | $15 | $— |
| Deferred financing costs included in accounts payable and accrued expenses | $— | $202 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.